G Ragupathi

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm
    G Ragupathi
    Clinical Immunology Service, Memorial Hospital, New York, NY 10021, USA
    Glycoconj J 15:217-21. 1998
  2. pmc Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA
    Vaccine 28:4260-7. 2010
  3. pmc Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Immunol Immunother 58:1397-405. 2009
  4. pmc Evaluation of widely consumed botanicals as immunological adjuvants
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    Vaccine 26:4860-5. 2008
  5. ncbi request reprint Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Clinic Immunology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5214-20. 2003
  6. ncbi request reprint A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 52:608-16. 2003
  7. pmc On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines
    Govindaswami Ragupathi
    Laboratory of Tumor Vaccinology, Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:13699-704. 2002
  8. ncbi request reprint Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies
    Govindaswami Ragupathi
    Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 99:207-12. 2002
  9. ncbi request reprint Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines
    Govindaswami Ragupathi
    Laboratory of Tumor Vaccinology, Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Vaccine 20:1030-8. 2002
  10. pmc Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Expert Rev Vaccines 10:463-70. 2011

Collaborators

Detail Information

Publications21

  1. ncbi request reprint A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm
    G Ragupathi
    Clinical Immunology Service, Memorial Hospital, New York, NY 10021, USA
    Glycoconj J 15:217-21. 1998
    ..This method gave a higher epitope ratio and yield than the direct method. The STn(c)-MMCCH-KLH conjugate induced high titer antibodies in mice against STn(c). This method may be generally applicable for large synthetic oligosaccharides...
  2. pmc Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA
    Vaccine 28:4260-7. 2010
    ..This lays the foundation for future exploration of structure-function correlations to enable the discovery of novel saponins with increased potency, enhanced stability, and attenuated toxicity...
  3. pmc Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Immunol Immunother 58:1397-405. 2009
    ..This vaccine is ready for testing as an active immunotherapy for treating sLe(a) positive cancer in clinical settings...
  4. pmc Evaluation of widely consumed botanicals as immunological adjuvants
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    Vaccine 26:4860-5. 2008
    ..We describe here the results obtained using this s.c. immunization model with seven botanicals purported to have immune stimulant effects...
  5. ncbi request reprint Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Clinic Immunology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5214-20. 2003
    ..However, vaccination of patients with GD2-KLH has previously failed to induce a consistent relevant antibody response. We test here whether the use of GD2 lactone-KLH can overcome the low immunogenicity of GD2-KLH...
  6. ncbi request reprint A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 52:608-16. 2003
    ..4). An optimal dose of saponin adjuvant, QS-21 (50 microg) or GPI-0100 (1000 microg), is required for optimal antibody titers. This heptavalent vaccine is sufficiently optimized for testing in the clinic...
  7. pmc On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines
    Govindaswami Ragupathi
    Laboratory of Tumor Vaccinology, Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:13699-704. 2002
    ..The results demonstrate that single vaccine constructs bearing several different carbohydrate antigens have the potential to stimulate a multifaceted immune response...
  8. ncbi request reprint Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies
    Govindaswami Ragupathi
    Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 99:207-12. 2002
    ..Based on the results of our study, a KH-1-KLH plus QS-21 vaccine is being prepared for clinical evaluation...
  9. ncbi request reprint Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines
    Govindaswami Ragupathi
    Laboratory of Tumor Vaccinology, Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Vaccine 20:1030-8. 2002
    ..Immunogenicity of the four individual antigens conjugated to KLH and QS-21 is not affected by mixing the four together and administering them at a single subcutaneous site...
  10. pmc Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Expert Rev Vaccines 10:463-70. 2011
    ....
  11. ncbi request reprint Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21
    G Ragupathi
    Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 85:659-66. 2000
    ..Sera obtained from 4 of these 6 patients showed cell surface reactivity by FACS and from 2 showed strong cell surface reactivity by immune adherence (IA) assay and complement lysis against the GD3 positive cell line SK-Mel-28...
  12. ncbi request reprint Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells
    G Ragupathi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immunol Immunother 48:1-8. 1999
    ....
  13. ncbi request reprint Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience
    C Musselli
    Memorial Sloan Kettering Cancer Center, Department of Tumor Vaccinology, New York, NY 10021, USA
    J Cancer Res Clin Oncol 127:R20-6. 2001
    ..Randomized phase II trials with polyvalent vaccines are planned for initiation in 2001-2002 in patients with ovarian, breast, and prostate cancer...
  14. pmc Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
    S F Slovin
    Division of Genitourinary Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 96:5710-5. 1999
    ....
  15. ncbi request reprint A second generation synthesis of the MBr1 (globo-H) breast tumor antigen: new application of the n-pentenyl glycoside method for achieving complex carbohydrate protein linkages
    J R Allen
    Laboratory of Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, New York, NY 10021, USA
    Chemistry 6:1366-75. 2000
    ..This group serves as an anomeric protecting group and as a linker for bioconjugation to carrier protein. The resultant synthesis allows for the production of suitable quantities of globo-H for clinical trials...
  16. pmc Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21
    S Adluri
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Cancer 79:1806-12. 1999
    ....
  17. pmc Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial
    T Gilewski
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, Laboratories of Bio-Organic Chemistry, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 98:3270-5. 2001
    ..Affinity column purification supported the specificity of IgM antibodies for globo H. On the basis of these data, globo H will constitute one component of a polyvalent vaccine for evaluation in high-risk breast cancer patients...
  18. ncbi request reprint Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy
    P O Livingston
    Department of Medicine, Clinical Immunology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 54:1018-25. 2005
    ..These findings support our plan to develop a tetravalent vaccine against SCLC targeting GM2, fucosyl GM1, globo H and polysialic acid...
  19. ncbi request reprint Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization
    Maria K Spassova
    Organic Synthesis Core Facility, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Org Chem 70:3383-95. 2005
    ....
  20. ncbi request reprint Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine
    Susan F Slovin
    Genitourinary Solid Tumor Service, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:4292-8. 2003
    ....
  21. ncbi request reprint Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1
    Cristina Musselli
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 97:660-7. 2002
    ..Assuming this criteria, convincing induction of T-cell immunity against MUC1 by vaccination has yet to be described...